SAN FRANCISCO--(BUSINESS WIRE)--For biotech the summer months of July and August are typically slow as far as the capital markets are concerned. However, the announcement that Roche made a bid of almost $44 billion for the 44% remaining shares of Genentech it didn’t already own certainly galvanized investors’ attention as they rushed into biotech stocks in light of the offer, reasoning that more deals may be in the offing.
